Attovia Therapeutics IPO: Can This $200M Biotech Debut Spark NASDAQ Growth?
Clinical-stage biopharmaceutical company Attovia Therapeutics files for NASDAQ IPO under ticker ATTO to raise up to $200 Million. Discover its drug pipelines and target valuation.
